ArticleTargeted oncology2019
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion.
Silvia La Monica et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
24 papers cite it
this papercites it